Tafasitamab Regimen Improves Survival Outcomes in Newly Diagnosed High-Risk DLBCL

Adding tafasitamab and lenalidomide to standard R-CHOP chemotherapy significantly reduced the risk of disease progression or death in patients with newly diagnosed, high-risk diffuse large B-cell lymphoma (DLBCL), according to phase 3 results from the frontMIND trial (NCT04824092) presented at the 2026 American Society of Clinical Oncology Annual Meeting.

DLBCL Statistics and Treatment

DLBCL comprises a heterogeneous group of lymphoid malignancies characterized by diverse pathological, clinical, and molecular features that arise from mature B cells at different stages of differentiation. According to the World Health Organization, DLBCL is the most prevalent lymphoid neoplasm accounting for 80% of all aggressive lymphomas and approximately 40% of all non–Hodgkin lymphoma cases around the world. DLBCL has a 5-year survival rate of about 65%, which decreases with age, and a mortality rate of about 1.8 per 100,000 for both men and women.¹

For over 20 years, the standard of care for patients with DLBCL has been 4 to 6 cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone—known as R-CHOP—depending on disease stage. Despite its efficacy and well-established clinical use, R-CHOP leaves approximately 40% of DLBCL patients without a durable cure, creating a persistent unmet need for more effective first-line regimens.²

frontMIND was designed to address that gap by evaluating whether tafasitamab (Monjuvi; Incyte Corporation)—a CD19-targeting monoclonal antibody—combined with lenalidomide (Revlimid; Bristol Myers Squibb) could meaningfully enhance the backbone of R-CHOP in a high-risk population.

Tafasitamab is a CD19-targeting monoclonal antibody with an engineered Fc region designed to increase affinity for immune effector cells such as natural killer cells. Presenting the data, study investigator Andreas Rosenwald explained that combining tafasitamab with lenalidomide is supported by extensive preclinical evidence demonstrating synergistic activity. According to Rosenwald, lenalidomide expands and activates effector cells, enhancing multiple mechanisms of tafasitamab-mediated tumor cell death, including antibody-dependent cellular cytotoxicity, antibody-dependent cellular phagocytosis, and direct cell killing.

“There is a lot of preclinical data clearly implying that there's a synergy,” said Georg Lenz, MD, PhD, from the University Hospital of Münster, Department of Internal Medicine, during the presentation.

frontMIND Study Design and Key Data Takeaways

frontMIND was a double-blind, placebo-controlled phase 3 trial that enrolled 899 patients aged 18 to 80 years with newly diagnosed high-intermediate or high-risk DLBCL or high-grade B-cell lymphoma (HGBL), defined by an IPI score of 3 to 5 or aaIPI of 2 to 3 in patients 60 years of age or younger. Patients were randomly assigned to receive tafasitamab plus lenalidomide and R-CHOP or R-CHOP alone.

Investigators intentionally selected a particularly high-risk patient population. To ensure enrollment of patients requiring immediate treatment, the interval between diagnosis and treatment initiation was limited to 20 days or less. Baseline characteristics reflected the aggressive nature of the study population, with more than 80% of patients presenting with elevated lactate dehydrogenase levels, over 30% having an ECOG performance status of 2, and more than 40% classified as high risk by IPI or age-adjusted IPI criteria.

The primary end point was investigator-assessed progression-free survival (PFS), with key secondary end points including event-free survival (EFS), overall survival (OS), complete response (CR), and overall response rate (ORR).

At the primary analysis, conducted with a data cutoff of October 20, 2025, and a median follow-up of about 35.2 months, tafasitamab plus lenalidomide and R-CHOP achieved a statistically significant improvement in PFS compared with R-CHOP alone, with a hazard ratio of 0.75 (95% CI, 0.59-0.96; P = 0.019). This corresponded to a 25% reduction in the risk of disease progression or death. Rosenwald emphasized both the statistical and clinical significance of the findings.

At 24 months, approximately 71.1% of patients receiving tafasitamab plus lenalidomide and R-CHOP remained progression-free compared with 62.9% of patients receiving R-CHOP alone, representing an absolute improvement of 8.2%. Among patients with centrally confirmed lymphoma diagnoses, the difference increased to 10.5%, with 24-month PFS rates of 72.7% and 62.2%, respectively.

In the subgroup of patients with centrally confirmed lymphoma subtypes (n = 773), the PFS benefit was more pronounced, with an HR of 0.68 (95% CI, 0.52-0.88) and 24-month PFS rates of 72.7% versus 62.2%. PFS improvement was observed across both molecular cell-of-origin subtypes—activated B-cell and germinal center B-cell—a finding with important implications for patient selection given the historically differential response to therapy by COO subtype.

EFS was also significantly improved with tafasitamab plus lenalidomide and R-CHOP (HR 0.79; 95% CI, 0.64-0.97; P = .026). CR and ORR rates were comparable between arms, and the OS hazard ratio favored the experimental arm at 0.85, though this did not reach statistical significance at this interim timepoint, with final OS analysis planned at 5 years.

The safety profile was consistent with the known effects of each agent. Any-grade treatment-emergent adverse events (TEAEs) were similar across arms (98.6% vs 97.1%), though grade 3 or higher TEAEs were more frequent with tafasitamab plus lenalidomide and R-CHOP (86.7% vs 76.1%). Discontinuation rates due to TEAEs were 25.7% and 17.9% of patients, and TEAE-related deaths occurred in 5.9% and 3.8%, respectively. Notably, overall mortality was lower in the experimental arm (18.5% vs 21.7%).

Although hematologic toxicities (eg, neutropenia, thrombocytopenia, anemia, febrile neutropenia) occurred more frequently with the addition of tafasitamab and lenalidomide, investigators reported that these adverse effects were generally manageable. Rosenwald noted that the trial was conducted between May 2021 and March 2023 during the COVID-19 pandemic, which contributed to higher rates of infectious disease-related complications, including COVID-19-related deaths, sepsis, and pneumonia.

“Tafasitamab plus lenalidomide and R-CHOP does not compromise the R-CHOP background,” Rosenwald said. “I think that's very important, because we've seen that in other studies that the R-CHOP backbone is compromised. This is not the case by the addition of [tafasitamab and lenalidomide].”

Redefining the Standard of Care

For more than 2 decades, R-CHOP has remained the frontline standard for DLBCL despite substantial rates of relapse and refractory disease among high-risk patients. The frontMIND results represent one of the strongest demonstrations to date that adding targeted immunotherapy to R-CHOP can improve outcomes in this setting. With significant improvements in PFS and EFS and evidence of benefit across molecular subtypes, tafasitamab plus lenalidomide and R-CHOP may help redefine first-line treatment for high-risk DLBCL and HGBL, pending longer-term survival data and regulatory review.

REFERENCES

1. Berhan A, Almaw A, Damtie S, Solomon Y. Diffuse large B cell lymphoma (DLBCL): epidemiology, pathophysiology, risk stratification, advancement in diagnostic approaches and prospects: narrative review. Discov Oncol. Published February 15, 2025. doi:10.1007/s12672-025-01958-w

2. Ansell SM, Nowakowski GS. Current treatment algorithm: diffuse large B cell lymphoma. Blood Cancer Journal. March 10, 2026. doi.org/10.1038/s41408-026-01458-2

3. Lenz G, Burke JM, Nowakowski GS, et al. frontMIND: Phase 3 study of tafasitamab (Tafa) plus lenalidomide (len) and R-CHOP for patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL). Presented at: ASCO 2026. May 28-June 2, 2026. Chicago, IL. Abstract LBA7000